Gilead Sciences, Inc. is a favored stock by Jim Simons' Renaissance Technologies, but may face challenges due to potential price cuts on its key HIV drug Biktarvy. RBC analysts estimate a revenue drop, but uncertainties exist. GILD focuses on therapies for viral diseases and cancer.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing